Cabotegravir is a medicine used to help prevent HIV. It is usually given as a shot into the buttock muscle every two months, and it also comes as a pill. It works by blocking a step the virus needs to take over the body's cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Apretude (Cabotegravir) for Viral Sexually Transmitted Diseases?
Cabotegravir, given as the long-acting injection Apretude, is a form of HIV pre-exposure prophylaxis, or PrEP: medicine taken by someone who does not have HIV to lower their chance of getting it through sex. It is approved for adults and adolescents who weigh at least 35 kg (about 77 pounds) and are at risk of HIV. For people who find a daily pill hard to keep up with, or would rather not carry one, an injection every two months is the main appeal. Cabotegravir also comes as Vocabria, a daily tablet used only for short stretches: as an optional trial month before the injections, or to cover injections a person knows they will miss. In HIV treatment, cabotegravir is paired with another HIV medicine, rilpivirine, in the injection Cabenuva. That is a different use with its own page. Apretude on its own is a prevention medicine, not a treatment for HIV.
HIV is a virus that copies its genetic material into the DNA of the immune cells it infects, using an enzyme called integrase. Once that copy is stitched in, the cell becomes a lasting source of new virus. Cabotegravir belongs to a group of HIV medicines called integrase inhibitors. It blocks that stitching step, so if the virus enters the body during sex, it is stopped before it can establish itself. Apretude is made as a slow-release suspension that is injected deep into a muscle and released gradually from there. That is why one injection keeps protective levels in the blood for about two months, and why small amounts stay in the body for a year or more after the last dose.
Apretude is given only by a healthcare provider, as a single injection into the muscle of the buttock. The first two injections are given one month apart, and after that one injection every two months. Each visit can fall up to 7 days before or after the scheduled date. Some people first take one Vocabria tablet daily for about a month to check that they tolerate cabotegravir before the long-acting injection, but going straight to injections is also an option. An HIV test is done before the first dose and again before every injection. Keeping to the schedule matters, because protection fades as levels drop. If you expect to miss an injection visit by more than 7 days, contact your prescriber right away: daily cabotegravir tablets or another PrEP option can cover the gap, and a long delay may mean restarting with two injections a month apart.
Reactions where the shot was given are by far the most common side effect: pain, tenderness, a firm lump, swelling, redness or bruising in the buttock. In the main trials, 82% of men and transgender women and 38% of cisgender women had at least one. Most were mild or moderate, lasted a few days to about a week, and became less frequent with later injections. Few people stopped because of them. Diarrhea, headache, a feverish or flu-like feeling, tiredness, trouble sleeping, nausea and dizziness were also reported. A few reactions are uncommon but important. Call your prescriber promptly about any new rash. Seek medical help right away if a rash comes with fever, blisters, mouth sores, red or swollen eyes, swelling of the face, lips or tongue, or trouble breathing, which can signal a severe allergic or skin reaction. Liver problems have also been reported: yellowing of the skin or eyes, dark tea-colored urine, pale stools or pain under the right ribs should be reported the same day. Depression, low mood and suicidal thoughts have been reported too, and new or worsening mood symptoms deserve prompt evaluation.
The most important warning concerns HIV that has not yet been diagnosed. Cabotegravir alone is not enough to control an established HIV infection, so if someone already has HIV, or acquires it while levels are present, the virus can become resistant to cabotegravir and related HIV medicines. That is why testing before every injection is required, why Apretude is not given to anyone whose HIV status is unknown, and why anyone who tests positive switches promptly to a full HIV treatment regimen. Some medicines speed up how fast the body clears cabotegravir and can make it ineffective. It cannot be used with the seizure medicines carbamazepine, oxcarbazepine, phenobarbital or phenytoin, or with the tuberculosis antibiotics rifampin or rifapentine. Rifabutin, another tuberculosis antibiotic, requires a changed injection schedule. Tell the prescriber and pharmacist about every medicine and supplement, including ones started after injections begin. Apretude does not protect against other sexually transmitted infections (STIs), such as gonorrhea, chlamydia or syphilis, so condoms and regular STI testing still matter. There is little information on its use in pregnancy, and because the drug lingers for a year or more after the last injection, anyone who is pregnant, planning pregnancy or breastfeeding should weigh this with their prescriber.
Expect a clinic visit every two months, each with an HIV test and an injection, and periodic testing for other STIs. How soon full protection begins after the first injection is not known, so ask how to stay protected in the early weeks. Mention any flu-like illness, such as fever, sore throat, swollen glands or a rash, especially after a possible exposure, because it can be an early sign of new HIV that a standard test may miss. In two large trials, people receiving injections every two months had far fewer new HIV infections than people taking daily Truvada pills: about two thirds fewer among men and transgender women who have sex with men, and close to 90% fewer among cisgender women. No PrEP is 100% effective, and missed visits weaken protection. Stopping is a planned step, not just skipping visits. Cabotegravir levels fall slowly over a year or more, and during that time they are too low to protect but can still allow resistance if HIV is acquired. Anyone still at risk should start another form of PrEP, such as daily pills or a different long-acting injection, within two months of the last shot.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Apretude (Cabotegravir), what you've noticed, or ask the community a question.